Pharmaco - Articles
27-Aug-2010
Parkinson's is a progressive neurological condition affecting movements such as walking, talking, and writing. It is named after Dr. James Parkinson (1755-1824), the London doctor who first identified Parkinson's as a specific condition.
Parkinson's occurs as result of a loss of nerve cells in the part of the brain known as the substantia nigra. These cells are responsible for producing a chemical known as dopamine, which allows messages to be sent to the parts of the brain that co-ordinate movement. With the depletion of dopamine-producing cells, these parts of the brain are unable to function normally. The main symptoms of Parkinson's can also be symptoms of other disorders. Conditions that produce these symptoms are known collectively as parkinsonism. Parkinson's is the most common f…
Parkinson's occurs as result of a loss of nerve cells in the part of the brain known as the substantia nigra. These cells are responsible for producing a chemical known as dopamine, which allows messages to be sent to the parts of the brain that co-ordinate movement. With the depletion of dopamine-producing cells, these parts of the brain are unable to function normally. The main symptoms of Parkinson's can also be symptoms of other disorders. Conditions that produce these symptoms are known collectively as parkinsonism. Parkinson's is the most common f…
All industries today face perpetual change and the need to cope with new challenges; nowhere is this trend more prevalent than in the life sciences industries, ie pharmaceuticals, biotech, diagnostics, medical devices and healthcare services.
In addition to the traditional market forces of competition, globalisation, changing customer requirements and input costs, life science companies must transform structure and working methods continually to meet their own particular business objectives. Life sciences companies ranging from the smallest biotech to the largest multinational pharmaceutical have to balance spending plans with the need to satisfy shareholders/investors. For recruitment companies in this sector the impact of all this change creates its own set of challenges, particularly wh…
In addition to the traditional market forces of competition, globalisation, changing customer requirements and input costs, life science companies must transform structure and working methods continually to meet their own particular business objectives. Life sciences companies ranging from the smallest biotech to the largest multinational pharmaceutical have to balance spending plans with the need to satisfy shareholders/investors. For recruitment companies in this sector the impact of all this change creates its own set of challenges, particularly wh…
With these increasing pressures upon the pharmaceuticals industry, it has never been more important to formulate an accurately informed pricing strategy
Examining HE strategies and requirements in major markets and producing an effective pricing policy - 30th September/1st October 2008, BSG House, London, UK - Now in its seventh year, The Annual Pricing & Reimbursement conference will provide you with the information and analysis you need to understand the dynamics of the market and create an effective pricing policy for both the forthcoming year and subsequent strategic development. This 2-day event will assist in better planning and marketing strategy and enable you to share your insights on this evolving industry issue. Key Industry Speakers Include - Anne-Toni Rodgers, Dire…
Examining HE strategies and requirements in major markets and producing an effective pricing policy - 30th September/1st October 2008, BSG House, London, UK - Now in its seventh year, The Annual Pricing & Reimbursement conference will provide you with the information and analysis you need to understand the dynamics of the market and create an effective pricing policy for both the forthcoming year and subsequent strategic development. This 2-day event will assist in better planning and marketing strategy and enable you to share your insights on this evolving industry issue. Key Industry Speakers Include - Anne-Toni Rodgers, Dire…
27-Aug-2010
This feature 'What is Psoriasis?' is one of three features that focuses on the topic of skin conditions.
Mild psoriasis (80% of people) is where there are a few patches that may need treatment but are not likely to cause problems and can be easily controlled. Moderate psoriasis (15% of people) is where more skin is involved and the condition is widespread but again can usually be controlled with self management under a GP or nurse supervision. Severe psoriasis (5% of people) is where large areas are covered with psoriasis and the condition becomes difficult to self-manage or no longer responds to treatment. At this stage referral to secondary care at a local hospital out-patient department or in extreme cases an in-patient stay may be felt necessary in order to provide optimum care and mo…
Mild psoriasis (80% of people) is where there are a few patches that may need treatment but are not likely to cause problems and can be easily controlled. Moderate psoriasis (15% of people) is where more skin is involved and the condition is widespread but again can usually be controlled with self management under a GP or nurse supervision. Severe psoriasis (5% of people) is where large areas are covered with psoriasis and the condition becomes difficult to self-manage or no longer responds to treatment. At this stage referral to secondary care at a local hospital out-patient department or in extreme cases an in-patient stay may be felt necessary in order to provide optimum care and mo…
27-Aug-2010
This feature 'What is Eczema?' is one of three features that focuses on the topic of skin conditions.
Eczema is a very common condition, and it affects all races and ages, including young infants. About 1-2 percent of adults have eczema, and as many as 20 percent of children are affected. It usually begins early in life, even before asthma or hay fever. Most affected individuals have their first episode before age 5 years. For some, the disease will improve with time. For others, however, eczema is a chronic or recurrent disorder. Although it can occur just once, it usually occurs on and off throughout life, or lasts the entire lifetime. Eczema can be a difficult, frustrating condition. The natural human desire to scratch or rub an itchy rash just makes the condition worse, and treatments…
Eczema is a very common condition, and it affects all races and ages, including young infants. About 1-2 percent of adults have eczema, and as many as 20 percent of children are affected. It usually begins early in life, even before asthma or hay fever. Most affected individuals have their first episode before age 5 years. For some, the disease will improve with time. For others, however, eczema is a chronic or recurrent disorder. Although it can occur just once, it usually occurs on and off throughout life, or lasts the entire lifetime. Eczema can be a difficult, frustrating condition. The natural human desire to scratch or rub an itchy rash just makes the condition worse, and treatments…
27-Aug-2010
This feature 'What is Acne?' is one of three features that focuses on the topic of skin conditions.
During puberty, the production of male sex hormones (androgens) increases in both girls and boys, which can stimulate the sebaceous glands to produce more sebum. In some people, the sebaceous glands are extremely sensitive to androgens. These people, mostly men, get acne so severely that they need medical treatment. The increased production of sebum makes the openings of the sebaceous glands narrower, which prevents the sebum from getting out. Meanwhile, the sebum production continues regardless. Pimples are often caused by Propionebacterium acnes, a common bacterium on the skin that feeds on sebum. This bacterium produces waste products and fatty acids that irritate the sebaceous glan…
During puberty, the production of male sex hormones (androgens) increases in both girls and boys, which can stimulate the sebaceous glands to produce more sebum. In some people, the sebaceous glands are extremely sensitive to androgens. These people, mostly men, get acne so severely that they need medical treatment. The increased production of sebum makes the openings of the sebaceous glands narrower, which prevents the sebum from getting out. Meanwhile, the sebum production continues regardless. Pimples are often caused by Propionebacterium acnes, a common bacterium on the skin that feeds on sebum. This bacterium produces waste products and fatty acids that irritate the sebaceous glan…
27-Aug-2010
The development of innovative therapeutics and complimentary technologies for the effective management of pain 7th – 8th October 2008, BSG Conference Centre, London, UK.
“The market revenue from drug-delivery technologies in the pain management market is US$1.9billion, growing at a CAGR of 6.5% to reach US$2.6billion by the end of 2012.” [‘Pain Market Outlook Report’ - Business Insights] - Dr Emanuele Sher, Research Advisor, Pain Migraine Team Leader, Eli Lilly & Co - Dr Mark Field, Global Research & Development, Pfizer - Dr Adnan Al-Kaisy, Senior Physician, Pain Management Clinic London - Professor Peter McNaughton, Professor of Pharmacology, University of Cambridge - Professor Praveen Anand, Professor of Clinical Neurology, Imperial College London - Dr Dic Williams, Research…
“The market revenue from drug-delivery technologies in the pain management market is US$1.9billion, growing at a CAGR of 6.5% to reach US$2.6billion by the end of 2012.” [‘Pain Market Outlook Report’ - Business Insights] - Dr Emanuele Sher, Research Advisor, Pain Migraine Team Leader, Eli Lilly & Co - Dr Mark Field, Global Research & Development, Pfizer - Dr Adnan Al-Kaisy, Senior Physician, Pain Management Clinic London - Professor Peter McNaughton, Professor of Pharmacology, University of Cambridge - Professor Praveen Anand, Professor of Clinical Neurology, Imperial College London - Dr Dic Williams, Research…
27-Aug-2010
Arthritis is not just a disease of older people – it can affect people of all ages, including children. It is not clear what causes arthritis and there is no cure at present. However, there is plenty you can do to manage yourcondition and lead a full and active life.
Arthritis is not just a disease of older people – it can affect people of all ages, including children. It is not clear what causes arthritis and there is no cure at present. However, there is plenty you can do to manage yourcondition and lead a full and active life. Two of the most common forms of arthritis are osteoarthritis (OA) and rheumatoid arthritis(RA). Osteoarthritis (OA) Osteoarthritis is a very common condition, affecting the joints, often described as "wear and tear" arthritis. This can start from our teens and…
Arthritis is not just a disease of older people – it can affect people of all ages, including children. It is not clear what causes arthritis and there is no cure at present. However, there is plenty you can do to manage yourcondition and lead a full and active life. Two of the most common forms of arthritis are osteoarthritis (OA) and rheumatoid arthritis(RA). Osteoarthritis (OA) Osteoarthritis is a very common condition, affecting the joints, often described as "wear and tear" arthritis. This can start from our teens and…
27-Aug-2010
Finally a comprehensive source for the very latest performance metrics and trend analysis on every key aspect of the new drug approval processThe US Drug Approval Trends and Yearbook 2006/2007!
In this first-of-its-kind compendium, we examine hundreds of key trends and metrics to provide industry with all-new benchmarks and metrics on which to assess their own performance, to plan their own R&D projects, and to assess the various drug approval options and strategies available to them. The US Drug Approval Trends and Yearbook 2006/2007 provides an unprecedented number of in-depth analyses and benchmarks, including the following: - NDA and NME first-cycle success rates, review outcomes, and trends - Complete review and approval profiles for each NME and NDA, including cycles to appro…
In this first-of-its-kind compendium, we examine hundreds of key trends and metrics to provide industry with all-new benchmarks and metrics on which to assess their own performance, to plan their own R&D projects, and to assess the various drug approval options and strategies available to them. The US Drug Approval Trends and Yearbook 2006/2007 provides an unprecedented number of in-depth analyses and benchmarks, including the following: - NDA and NME first-cycle success rates, review outcomes, and trends - Complete review and approval profiles for each NME and NDA, including cycles to appro…
Cimzia (certolizumab pegol) is the first and so far, only, PEGylated, Fc-Free, anti-tumour necrosis factor (TNF) alpha treatment in development for rheumatoid arthritis. Data presented at the Annual European Rheumatology Congress (EULAR) suggest that, in combination with methotrexate, Cimzia acts fast to significantly suppress disease activity, prevent structural damage to joints, preserve physical function and help patients continue working productively.
Certolizumab pegol (Cimzia) is a PEGylated Fc-free anti-TNF alpha agent, administered subcutaneously, and currently licensed in the US and Switzerland for treatment of Crohn’s Disease. By not having the Fc region present in conventional anti-TNFs, Cimzia retains the potency of anti-TNFs without the possible cytotoxicity mediated by Fc. In…
Certolizumab pegol (Cimzia) is a PEGylated Fc-free anti-TNF alpha agent, administered subcutaneously, and currently licensed in the US and Switzerland for treatment of Crohn’s Disease. By not having the Fc region present in conventional anti-TNFs, Cimzia retains the potency of anti-TNFs without the possible cytotoxicity mediated by Fc. In…
Of patients with lung cancer, 80 per cent have non-small cell lung cancer (NSCLC) and of those, 40 per cent are not diagnosed until their disease is advanced and has spread to other organ sites. Current targeted treatment has improved survival but is not suitable for all. Now a new trial, FLEX, shows adding the targeted therapy Erbitux (cetuximab) to chemotherapy increases survival for all types of NSCLC.
Worldwide, lung cancer is the most common cause of cancer-related death in men and the second most common in women – breast cancer being the most common. Almost one million men and 376,00 women die from the disease each year. Overall, five-year survival is about 16 per cent, which compares poorly to five-year survival rates for colon cancer (65 per cent), breast cancer (89 per cent) and…
Worldwide, lung cancer is the most common cause of cancer-related death in men and the second most common in women – breast cancer being the most common. Almost one million men and 376,00 women die from the disease each year. Overall, five-year survival is about 16 per cent, which compares poorly to five-year survival rates for colon cancer (65 per cent), breast cancer (89 per cent) and…
27-Aug-2010
The 'Scanning New Horizons in Rheumatoid Arthritis' Media Briefing is an innovative global press event featuring presentations by internationally renowned experts: Professor Paul Emery, Professor Robert Moots and Professor Bengt Jansson.
The 'Scanning New Horizons in Rheumatoid Arthritis' Media Briefing is an innovative global press event featuring presentations by internationally renowned experts: Professor Paul Emery, Professor Robert Moots and Professor Bengt Jansson. Key Highlight: • New radiographic remission data from the COMET (COmbination of Methotrexate and ETanercept in early active rheumatoid arthritis) study and what the one year results will mean for patients and for the future management of inflammatory conditions Live Webcast Details Journalists who are unable to attend…
The 'Scanning New Horizons in Rheumatoid Arthritis' Media Briefing is an innovative global press event featuring presentations by internationally renowned experts: Professor Paul Emery, Professor Robert Moots and Professor Bengt Jansson. Key Highlight: • New radiographic remission data from the COMET (COmbination of Methotrexate and ETanercept in early active rheumatoid arthritis) study and what the one year results will mean for patients and for the future management of inflammatory conditions Live Webcast Details Journalists who are unable to attend…
The EU GMPs were updated this year in February. As a result, Risk Management is a regulatory requirement and ICH Q9 is now Annex 20. EU regulators have also indicated that ICH Q10 on Pharmaceutical Quality Systems will become Annex 21 to the GMPs in June 2008 – sometime this month!
The EU GMPs were updated this year in February. As a result, Risk Management is a regulatory requirement and ICH Q9 is now Annex 20. EU regulators have also indicated that ICH Q10 on Pharmaceutical Quality Systems will become Annex 21 to the GMPs in June 2008 – sometime this month! In line with these proposed revisions, Magenta Global is pleased to bring you 2 courses on critical issues in biopharmaceutical and medical devices manufacturing. This is your timely chance to review the latest global initiatives…
The EU GMPs were updated this year in February. As a result, Risk Management is a regulatory requirement and ICH Q9 is now Annex 20. EU regulators have also indicated that ICH Q10 on Pharmaceutical Quality Systems will become Annex 21 to the GMPs in June 2008 – sometime this month! In line with these proposed revisions, Magenta Global is pleased to bring you 2 courses on critical issues in biopharmaceutical and medical devices manufacturing. This is your timely chance to review the latest global initiatives…
Kidney cancer patients who receive treatment with the orally-administered tyrosine kinase inhibitor sunitinib (Sutent) are living twice as long as patients who receive only interferon alpha treatment, according to data from a Phase III study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Survival now exceeds two years.
Overall survival data from a randomised double blind study comparing first-line sunitinib (Sutent) with the previous standard therapy in metastatic renal cell cancer (mRCC), interferon (IFN) alpha, show sunitinib extends median survival to almost two and a half years. This finding breaks new ground and more than doubles the survival time typically observed with IFN alpha treatment, say experts. Sunitininb, a multi-targete…
Overall survival data from a randomised double blind study comparing first-line sunitinib (Sutent) with the previous standard therapy in metastatic renal cell cancer (mRCC), interferon (IFN) alpha, show sunitinib extends median survival to almost two and a half years. This finding breaks new ground and more than doubles the survival time typically observed with IFN alpha treatment, say experts. Sunitininb, a multi-targete…
We have an enviable position of being visited by over 150,000 people each month looking for pharmaceutical news and jobs, and we need to satisfy their desire for content.
To do this, we need your expertise and your contributions. We are currently compiling a list of contributors who can either provide us with ad-hoc content through our news distribution service (press releases and features) or whom we can contact when we have specific requirements for editorial features. To become part of the PharmiTeam simply complete this quick registration form. PharmiWeb Statistics • 150,000+ visitors each month • 6500+ live jobs opportunities • 3000-4000 job applications processed each month • 20,000+ subscribed users receive our eNewsletter each week. • We publish on average 100 press releas…
To do this, we need your expertise and your contributions. We are currently compiling a list of contributors who can either provide us with ad-hoc content through our news distribution service (press releases and features) or whom we can contact when we have specific requirements for editorial features. To become part of the PharmiTeam simply complete this quick registration form. PharmiWeb Statistics • 150,000+ visitors each month • 6500+ live jobs opportunities • 3000-4000 job applications processed each month • 20,000+ subscribed users receive our eNewsletter each week. • We publish on average 100 press releas…
27-Aug-2010
It is estimated that one in two smokers will die from a smoking related disease, causing, on average, six to eight years of life lost per smoker. Smokers can also impact the health of those around them, for example their children, through passive smoking.
It is estimated that one in two smokers will die from a smoking related disease, causing, on average, six to eight years of life lost per smoker. Smokers can also impact the health of those around them, for example their children, through passive smoking. Facts : What does a cigarette contain? Tobacco smoke contains around 4,000 chemicals - here's just a few of them and their impact on the body: Nicotine : A drug that stimulates the brain and keeps people hooked on smoking. If you are a regular smoker, when the blo…
It is estimated that one in two smokers will die from a smoking related disease, causing, on average, six to eight years of life lost per smoker. Smokers can also impact the health of those around them, for example their children, through passive smoking. Facts : What does a cigarette contain? Tobacco smoke contains around 4,000 chemicals - here's just a few of them and their impact on the body: Nicotine : A drug that stimulates the brain and keeps people hooked on smoking. If you are a regular smoker, when the blo…
27-Aug-2010
“By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, research has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities.
A new Report from Visiongain. “By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities. This high-level management report examines the commercial prospects for anti-obesity prescription drugs in the global healthcare market. With obesity now the most common nutritional disorder…
A new Report from Visiongain. “By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities. This high-level management report examines the commercial prospects for anti-obesity prescription drugs in the global healthcare market. With obesity now the most common nutritional disorder…
27-Aug-2010
PharmiWeb.com May monthly focus feature highlighting the symptoms and various treatments for Crohn’s disease.
Who's affected?Approximately 1 in 1,500 people have Crohn's disease, and the condition affects slightly more women than men. It can develop at any age, but usually starts between the ages of 15 and 40. In Europe and North America, it most commonly affects Caucasians. The precise cause of Crohn's is unknown. The condition can run in families and is three times more common in smokers. Not smoking may reduce the risk of developing the disease. What are the symptoms?Symptoms occur when part of the gut becomes inflamed. Typical symptoms include: Diarrhoea, abdominal pain, fever, loss of appetite and weight loss, feeling generally unwell, and extreme tiredness. The symptoms vary depen…
Who's affected?Approximately 1 in 1,500 people have Crohn's disease, and the condition affects slightly more women than men. It can develop at any age, but usually starts between the ages of 15 and 40. In Europe and North America, it most commonly affects Caucasians. The precise cause of Crohn's is unknown. The condition can run in families and is three times more common in smokers. Not smoking may reduce the risk of developing the disease. What are the symptoms?Symptoms occur when part of the gut becomes inflamed. Typical symptoms include: Diarrhoea, abdominal pain, fever, loss of appetite and weight loss, feeling generally unwell, and extreme tiredness. The symptoms vary depen…
27-Aug-2010
Obesity is the heavy accumulation of fat in your body to such a degree that it rapidly increases your risk of diseases that can damage your health and knock years off your life, such as heart disease and diabetes.
The fat may be equally distributed around the body or concentrated on the stomach (apple-shaped) or the hips and thighs (pear-shaped). For medical purposes, the body mass index (BMI) is used to determine if your weight is in the healthy range. Doctors use BMI because it compares your weight against your height. Work out your BMI The BMI figures used in this article apply to adults only. Doctors use special charts to work out BMI for children to take account of differing rates of growth and development. Take your weight (kg) and divide it by the square of your height (m). For e…
The fat may be equally distributed around the body or concentrated on the stomach (apple-shaped) or the hips and thighs (pear-shaped). For medical purposes, the body mass index (BMI) is used to determine if your weight is in the healthy range. Doctors use BMI because it compares your weight against your height. Work out your BMI The BMI figures used in this article apply to adults only. Doctors use special charts to work out BMI for children to take account of differing rates of growth and development. Take your weight (kg) and divide it by the square of your height (m). For e…
Designed for those with Responsibilities in
Medical Affairs, R&D and Medical Science
Liaison Function Across the Pharmaceutical,
Biotechnology and Medical Device Industries
This Leadership Conference Focuses on: - Targeting Trends - Understanding Health Policy Changes - Image Improvement - Innovative Thinking
This Leadership Conference Focuses on: - Targeting Trends - Understanding Health Policy Changes - Image Improvement - Innovative Thinking
